Characteristics | Total subjects | p-value | Matched subjects | p-value | ||
---|---|---|---|---|---|---|
CHM users | Non-CHM users | CHM users | Non-CHM users | |||
(N = 149) | (N = 577) | (N = 149) | (N = 298) | |||
N (%) | N (%) | N (%) | N (%) | |||
Age (Mean ± SD) | 53.40 ± 12.54 | 54.82 ± 14.17 | 0.265 | 53.40 ± 12.54 | 54.47 ± 13.3 | 0.249 |
Gender | 0.036 | 1.000 | ||||
 Male | 106 (71.14%) | 457 (79.2%) | 106 (71.14%) | 212 (71.14%) | ||
 Female | 43 (28.86%) | 120 (20.8%) | 43 (28.86%) | 86 (28.86%) | ||
Charlson comorbidity index score (Mean ± SD) | 4.34 ± 2.12 | 4.65 ± 2.41 | 0.151 | 4.34 ± 2.12 | 4.21 ± 2.39 | 0.389 |
Interferon therapy | 2 (1.34%) | 3 (0.52%) | 0.279 | 2 (1.34%) | 3 (1.01%) | 0.750 |
Anti-virus therapy | 2 (1.34%) | 3 (0.52%) | 0.279 | 2 (1.34%) | 3 (1.01%) | 0.750 |
Income | 0.006 | 0.017 | ||||
  < NT20,000 | 81 (54.36%) | 387 (67.07%) | 81 (54.36%) | 198 (66.44%) | ||
 NT20,000-NT30,000 | 40 (26.85%) | 128 (22.18%) | 40 (26.85%) | 69 (23.15%) | ||
 ≧NT30,000 | 28 (18.79%) | 62 (10.75%) | 28 (18.79%) | 31 (10.4%) | ||
Urbanization level | 0.553 | 0.538 | ||||
 1 | 77 (55.40%) | 296 (53.72%) | 77 (55.4%) | 152 (53.15%) | ||
 2 | 40 (28.78%) | 146 (26.50%) | 40 (28.78%) | 76 (26.57%) | ||
 3 | 22 (15.83%) | 109 (19.78%) | 22 (15.83%) | 58 (20.28%) |